Interventional Cardiology

This cardiac subspecialty uses minimally invasive, catheter-based technologies in a cath lab to diagnose and treat coronary artery disease (CAD). The main focus in on percutaneous coronary interventions (PCI) to revascularize patients with CAD that is causing blockages resulting in ischemia or myocardial infarction. PCI mainly consists of angioplasty and implanting stents. Interventional cardiology has greatly expanded in scope over recent years to include a number of transcatheter structural heart interventions.

New SCAI President Dawn Abbott outlines workforce, training and inclusion priorities
SCAI President Dawn Abbott, MD, MSCAI, aims to turn attention toward the long-term sustainability of the interventional cardiology field.
Fewer stents, positive outcomes: Sirolimus-eluting balloons a safe alternative during PCI
Using a DCB that releases sirolimus over an extended period of time appears to be both safe and effective when treating patients who present with NSTEMI or unstable angina.
Popular weight loss drug linked to key benefits for patients undergoing TAVR, PCI
Two separate studies explored the value of treating heart patients with tirzepatide.
First bedside procedure of its kind performed by traveling clinicians on premature infant
The 22-week-old patient was successfully treated by a traveling cardiologist—all without being transported to the cath lab.
When bioprosthetic mitral valves fail: Redo surgery bests transcatheter treatment after 5 years
Short-term outcomes were comparable, but long-term data revealed a significant difference in all-cause mortality.

The Society for Cardiovascular Angiography and Interventions (SCAI) is entering a new chapter as Dawn Abbott, MD, MSCAI, who assumeed the presidency this week with a focus on strengthening the future of interventional cardiology through workforce development, expanded training pathways and continued efforts to broaden inclusion in the specialty. #SCAI2026 #SCAI26

New SCAI President Dawn Abbott outlines workforce, training and inclusion priorities

SCAI President Dawn Abbott, MD, MSCAI, aims to turn attention toward the long-term sustainability of the interventional cardiology field.

Cordis acquires MedAlliance, known for its drug-eluting balloon technology, in deal that could surpass $1B

Fewer stents, positive outcomes: Sirolimus-eluting balloons a safe alternative during PCI

Using a DCB that releases sirolimus over an extended period of time appears to be both safe and effective when treating patients who present with NSTEMI or unstable angina.

heart data research doctor cardiologist AI

Two separate studies explored the value of treating heart patients with tirzepatide.

Nicklaus Children’s Hospital patent ductus arteriosus (PDA) closure

First bedside procedure of its kind performed by traveling clinicians on premature infant

The 22-week-old patient was successfully treated by a traveling cardiologist—all without being transported to the cath lab.

When bioprosthetic mitral valves fail: Redo surgery bests transcatheter treatment after 5 years

Short-term outcomes were comparable, but long-term data revealed a significant difference in all-cause mortality.

cardiologists going through the certification process

Sirolimus- and paclitaxel-coated balloons deliver comparable 1-year PCI outcomes

Researchers explored data from more than 8,000 patients treated over a three-year period.

pulmonary hypertension denervation pulnovo medical

Medtronic leads $100M investment in artery denervation company

Pulnovo Medical, a global medtech company, plans on using the funds for clinical development, regulatory submissions, commercialization and much more.

FDA clears next-gen hybrid system for intravascular imaging

Conavi Medical's new hybrid imaging system simultaneously performs IVUS and OCT.